Market Place
Sourcing Support
Merck Advances Lung Cancer Strategy With Daiichi Deal And Combo Plans
06 Aug 2024 //
FIERCE BIOTECH
Merck completes acquisition of Harpoon Therapeutics
12 Mar 2024 //
INDIAN PHARMA POST
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
08 Jan 2024 //
BUSINESSWIRE
Harpoon Therapeutics Strengthens Leadership Team
26 Dec 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation
19 Dec 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in RRMM at ASH 2023
11 Dec 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation
02 Nov 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Announces Up to $150 Million Private Placement
23 Oct 2023 //
GLOBENEWSWIRE
Harpoon Announces Response Data From Phase 1/2 Trial Of T Cell Engager HPN328
21 Oct 2023 //
PRESS RELEASE
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented
16 Oct 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics to Present Data from Phase 1/2 Trial of HPN328
09 Oct 2023 //
GLOBENEWSWIRE
Harpoon Presents Hpn217 Interim Phase 1 Data At The Ims Annual Meeting
28 Sep 2023 //
PRESS RELEASE
Harpoon Announces First Patients with Small Cell Lung Cancer Dosed in HPN328
15 Sep 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Provides an Update on the HPN217 Development
13 Sep 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation
06 Sep 2023 //
GLOBENEWSWIRE
Harpoon to Participate in Two Upcoming Investor Conferences in September
05 Sep 2023 //
GLOBENEWSWIRE
Harpoon to Host KOL Event in Person and via Webcast on September 15, 2023
05 Sep 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics to Participate in Two Investor Conferences in August
03 Aug 2023 //
GLOBENEWSWIRE
Harpoon Appoints Haibo Wang as Senior Vice President of Business Development
01 Aug 2023 //
GLOBENEWSWIRE
Harpoon Announces Completion of Planned Patient in Phase 1 Study of HPN217
27 Jun 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Harpoon Presents Preclinical Results for T Cell HPN217 & HPN328 at AACR 2023
18 Apr 2023 //
GLOBENEWSWIRE
Harpoon Presents Data for New ProTriTAC Candidates in TROP2- and ITGB6
17 Apr 2023 //
GLOBENEWSWIRE
Harpoon to Participate in the Canaccord Horizons in Oncology Conference
10 Apr 2023 //
GLOBENEWSWIRE
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
27 Mar 2023 //
GLOBENEWSWIRE
Harpoon Reports Fourth Quarter and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
Harpoon Announces Acceptance of Five Abstracts for Presentation at AACR
14 Mar 2023 //
GLOBENEWSWIRE
Harpoon to Participate in the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Harpoon Presents Interim Results at ASH 2022 for Novel T Cell Engager HPN217 i
11 Dec 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call
05 Dec 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics to Participate in the Annual Healthcare Conference
21 Nov 2022 //
GLOBENEWSWIRE
Adamis, Harpoon, Neoleukin and Tricida grow biotech layoff wave
15 Nov 2022 //
FIERCEBIOTECH
Harpoon Updates Strategic Priorities and Reports 3Q 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Harpoon to Present Interim Results from Ph1 Trial of T Cell Engager HPN217
03 Nov 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
04 Oct 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors
19 Sep 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
01 Sep 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Reports Q2 Financial Results and Provides Corporate Update
10 Aug 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
02 Aug 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Expands Leadership Team
06 Jul 2022 //
GLOBENEWSWIRE
Harpoon Presents Interim Data from Ongoing Dose Escalation HPN328 Trial
26 May 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics and Roche to Collaborate on Clinical Trials
02 May 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform
12 Apr 2022 //
GLOBENEWSWIRE
Harpoon Tx to Participate in Canaccord Genuity Horizons in Oncology Conference
07 Apr 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Announces Leadership Change
07 Apr 2022 //
GLOBENEWSWIRE
Harpoon drug sunk by modest activity, tolerability issues
12 Mar 2022 //
FIERCEBIOTECH
Harpoon Tx Reports Q4 and FY 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Harpoon Tx Granted ODD for HPN328 for SCLC
07 Mar 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
02 Mar 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
09 Feb 2022 //
GLOBENEWSWIRE
Harpoon Therapeutics Provides Pipeline Update for TriTAC Clinical Programs
13 Dec 2021 //
GLOBENEWSWIRE
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on Dec 13, 2021
07 Dec 2021 //
GLOBENEWSWIRE
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at SITC
12 Nov 2021 //
GLOBENEWSWIRE
Harpoon CEO resigns in wake of dwindling market cap and sliding stock price
28 Oct 2021 //
ENDPTS
Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform
05 Oct 2021 //
GLOBENEWSWIRE
Harpoon Therapeutics Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Harpoon to Present Updated Interim Clinical Data for TriTAC® HPN424
18 May 2021 //
GLOBENEWSWIRE
